Understanding individual genetic variation can help predict chemotherapy side effects

March 23, 2012

The largest study ever on the effect of genetic variability on the toxicity of chemotherapy in breast cancer shows that it is possible to predict which patients are most likely to suffer serious side effects, a researcher will tell the 8th European Breast Cancer Conference (EBCC-8) today (Friday). Dr. Christof Vulsteke, from the Catholic University of Leuven, Belgium, will explain how his team's research is an important step towards achieving a personalised chemotherapy regime for each patient.

The researchers examined germline DNA from from 1089 who were treated between 2000 and 2010 with three commonly used chemotherapy drugs (fluorouracil, epirubicin and ). For each patient, the variability in the genes that are important for metabolising these three chemotherapeutic drugs was compared with the side effects experienced.

"We found that genetic variation in one gene was highly correlated with chemotherapy side effects," says Dr. Vulsteke. "Investigating this gene before starting chemotherapy would allow us to support the patient with either to increase the patient's immunity, or dose modifications, or a different better adapted to the patient, or a combination of these."

Currently, most patients receive the standard treatment; however, the side effects they suffer can be very different, ranging from severe to very minimal reactions. Making adjustments to treatment would have a major impact on both the physical and psychological well-being of patients, and on the to society posed by chemotherapy side effects, for example, hospitalisation.

The most important side effects of chemotherapy are mainly caused by immune system depression, which can result in potentially life threatening infections. Even though patients may take every precaution to avoid contamination, the vast majority of these infections are caused by naturally occurring microorganisms in the patient's own gastrointestinal tract. Other serious side effects noted in patients receiving chemotherapy are bleeding, severe infection of the mouth mucosa, severe bowel inflammation, nausea, and vomiting with dehydration.

"Our research has brought us one step closer towards prescribing personalised chemotherapy treatment with a minimum of side effects," says Dr. Vulsteke.

The researchers now intend to look for data from other European countries in order to further validate their results. They will also continue to follow up on their own patients; currently the patients are followed up, on average, for five years.

"In 2016 we will have a very accurate assessment of the impact of on survival and recurrence," says Dr. Vulsteke. "Our future research will focus on other genes involved in processing the chemotherapeutic drugs that we studied, and we will also enlarge the scope of the research by including other where we can hypothesise that genetic variability plays an equally important role," he will conclude.

Professor David Cameron, from the University of Edinburgh (Edinburgh, UK), and Chair of EBCC-8 said: "In the search for ways to "personalise" anti-cancer treatments, much of the focus has been on matching the treatment to the cancer. However it should not be forgotten that we also need to ensure the treatment is "matched" to the patient, and this study is an important step in this direction, potentially allowing us to ensure that standard chemotherapy can be delivered with either less severe toxicity, or perhaps to have the dose adjusted to give maximal benefit. Further studies will be needed to demonstrate that improvements in patient survival can be achieved by tailoring the actual doses along the lines that this study suggests could be possible."

Explore further: Gene responsible for relapses in young leukemia patients

Related Stories

Gene responsible for relapses in young leukemia patients

October 26, 2011

One of the causes of resistance to cancer treatment in children is now beginning to be elucidated. Acute lymphoblastic leukemia patients with a particular form of the ATF5 gene are at higher risk of having a relapse when ...

Recommended for you

Cancer can be combated with reprogrammed macrophage cells

May 20, 2016

Researchers at Karolinska Institutet have generated antibodies that reprogramme a type of macrophage cell in the tumour, making the immune system better able to recognise and kill tumour cells. The study, which is published ...

Taking control of key protein stifles cancer spread in mice

May 20, 2016

For cancer to spread, the cells that take off into the bloodstream must find a tissue that will permit them to thrive. They don't just go looking, though. Instead, they actively prepare the tissue, in one case by co-opting ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.